Strategic PR for Precisis – putting MedTech in focus

With EASEE®, Precisis is developing a medically approved subcutaneous brain stimulation system for the treatment of drug-resistant epilepsy – a pioneering product in a highly regulated, highly sensitive healthcare environment. Since 2023, Fullstop Public Relations has supported Precisis with its external communications, with the aim of expanding visibility in trade and consumer media, building trust in the technology and positioning the company as a thought leader in neuromodulation.

Epilepsy affects millions of people – yet very little is known about new treatment approaches in the German-speaking region. The challenge: bringing a clinically tested MedTech product that requires explanation into public awareness – in an environment marked by scepticism towards new technologies, a lack of differentiation in the market and heavy regulation. On top of this, there is a high need for trustworthy yet accessible communication – for both specialist audiences and patients.

Our PR strategy relies on well-founded media relations, scientific clarity and strong personalities. We developed a multi-stage communications concept that combines technical innovation with social relevance. Key components: a precise positioning of the new CEO, long-term studies prepared for editorial use, personal patient stories and an accompanying debate on the future of the MedTech industry in Germany. In close coordination with the Precisis team, content was steered along clinical, political and emotional communication axes.

The PR campaign generated more than 80 high-quality clippings in trade, business and consumer media – including pharma relations, MTD, DeviceMed, Health & Care Management, Monitor Versorgungsforschung, Startuprad.io and FAZ. The long-term study on the efficacy of the EASEE® system, showing a seizure reduction of more than 65% in patients, was communicated in the context of health policy reforms, among other things. The total reach was more than 540 million potential contacts, with an estimated media value of around €300,000. Precisis was successfully positioned as an innovative, trustworthy and evidence-based brand in the MedTech market – with lasting impact.